... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2022 Aflibercept Bevacizumab Dexamethasone Ranibizumab Triamcinolone acetonide Retinal vein occlusions (RVOs) are one of the leading causes of vision loss...

...Sadik Etka Bayramoglu; Nihat Sayin Introduction: In this study, we investigated the effect of drug dose on the progression of retinal vascularization in eyes treated with different doses of intravitreal bevacizumab (IVB). Methods: The patient charts of 259 eyes of 142 patients who were administered...

...Ori Segal; Roy Yavnieli; Michael Mimouni; Gilad Rabina; Noa Geffen; Elad Moisseiev; Arie Y. Nemet Purpose: This study aimed to identify baseline optical coherence tomography (OCT) factors in branch retinal vein occlusion (BRVO) that predict response to bevacizumab injections. Methods...

... factor Bevacizumab Endophthalmitis Filling Prefilled syringe Ranibizumab Syringe Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents are the most commonly performed procedure in ophthalmology [1-3]. These agents have been established as a safe and effective...

... Bevacizumab Ketorolac Prednisolone Carbonic anhydrase inhibitors Macular holes are full-thickness anatomic defects in the fovea from the internal limiting membrane (ILM) to the retinal pigment epithelium and are most commonly related to vitreous traction on the macula [1]. Because of the need...

...Omer Trivizki; Shulamit Schwartz; Neta Negri; Anat Loewenstein; Gilad Rabina; Shiri Shulman Purpose: To report a cluster of high incidence of noninfectious inflammatory reaction shortly after bevacizumab injection. Methods: Data were collected from medical records of consecutive patients who...

.... In this study, we investigate the effects of ranibizumab (Lucentis®), bevacizumab (Avastin®), and aflibercept (Eylea®) on primary human retinal pigment epithelial (hRPE) cells in vitro. Methods: hRPE cells were prepared from donor eyes and cultured under standard culture conditions. Scleral fibroblasts also...

...Sabit Kimyon; Alper Mete Purpose: To investigate the effects of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity (ROP) affecting zone 1. Methods: Files of the patients who received intravitreal bevacizumab (IVB) or ranibizumab (IVR) treatment for ROP affecting zone...

...Donghyoun Noh; Gahyung Ryu; Junyeop Lee; Min Sagong Purpose: To evaluate whether early anatomical and visual acuity (VA) responses to intravitreal bevacizumab (IVB) in macular edema secondary to branch retinal vein occlusion (BRVO) are associated with 1-year follow-up outcomes. Methods: Ninety-nine...

... at the Goldschleger Eye Institute, Sheba Medical Center, between the years 2007 and 2014. The study was approved by the local institutional review board and conducted in accordance with the Declaration of Helsinki. Age-related macular degeneration Anti-vascular endothelial growth factor Bevacizumab Long-term...

... with neovascular and dry AMD were enrolled. Eligible neovascular AMD patients received 2 intravitreal loading doses of either ranibizumab 0.5 mg or bevacizumab 1.25 mg at 4-week intervals and were subsequently followed every 4 weeks and treated according to a pro re nata regime for up to 1 year. Patients with dry...

...Muhammed Mustafa Kurt; Osman Çekiç; Çetin Akpolat; Murat Aslankurt; Mustafa Nuri Elçioğlu Purpose: The aim of this paper was to assess and compare the effects of intravitreal ranibizumab and bevacizumab on retinal vessel diameter in eyes with neovascular age-related macular degeneration (AMD...

...Joel Hanhart; Yaacov Rozenman Purpose: To compare the visual and anatomic outcomes of macular edema secondary to retinal vein occlusion after switching from bevacizumab to ranibizumab, aflibercept, or dexamethasone implant. Methods: Fifteen eyes were switched to ranibizumab, 12 to aflibercept...

...Emine Alyamaç Sukgen; Aysegül Çömez; Yusuf Koçluk; Selim Cevher Purpose: To compare the effects on the process of retinal vascularization of intravitreal ranibizumab (IVR) and intravitreal bevacizumab (IVB) in the treatment of severe retinopathy of prematurity. Methods: The present study is a bi...

...Rita Ehrlich; Idit Dan; Iris Deitch; Ruth Axer-Siegel; Karin Mimouni Purpose: To investigate the response to intravitreal ranibizumab after failure of intravitreal bevacizumab in patients with diabetic macular edema (DME). Methods: Demographics, visual acuity (VA), central macular thickness (CMT...

...Bianka Sobolewska; Cornelia Grimmel; Aikaterini Gatsiou; Kateryna Sopova; Judith Klein; Tilo Biedermann; Konstantinos Stellos; Focke Ziemssen Purpose: The aim of the study was to evaluate the potential influence of ranibizumab and bevacizumab on platelet activation and aggregation, which...

... after intravitreal bevacizumab (IVB) injections. Results: Regional choroidal thickness was measured in 57 eyes at baseline. The mean choroidal thickness of the occlusive area was significantly higher than that of the nonocclusive, subfoveal, and corresponding areas in the fellow eyes and normal controls...

... degeneration (AMD) switched from intravitreal bevacizumab or ranibizumab. Methods: This is a retrospective review of eyes with neovascular AMD switched to intravitreal aflibercept with at least 1 year of follow-up after the switch. All patients had had a minimum of 3 injections of bevacizumab or ranibizumab...

...João Pinheiro-Costa; Paulo Freitas-da-Costa; Manuel S. Falcão; Elisete M. Brandão; Fernando Falcão-Reis; Ângela M. Carneiro Objective: To compare outcomes after switching from intravitreal ranibizumab to bevacizumab in neovascular age-related macular degeneration (AMD). Methods: A retrospective...

... Ranibizumab Lucentis Bevacizumab Avastin Tachyphylaxis Resistance Age-related macular degeneration (AMD) is the most common cause of vision loss among elderly individuals in developed countries [ 1 ]. The exudative form of AMD is the severest form of the disease, with rapid vision loss due...